# A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults

> **NCT05040295** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 12 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** ritlecitinib
- **DRUG:** ritlecitinib
- **DRUG:** ritlecitinib

## Key facts

- **NCT ID:** NCT05040295
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-10
- **Primary completion:** 2021-11-19
- **Final completion:** 2021-11-19
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05040295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05040295, "A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05040295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*